Kwang Dong Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,707,288	1,659,512	1,640,719	1,514,454	1,431,545	1,338,182
Other Revenue	0	-	-	-	-	-0
Revenue	1,707,288	1,659,512	1,640,719	1,514,454	1,431,545	1,338,182
Revenue Growth	5.50%	1.15%	8.34%	5.79%	6.98%	7.59%
Cost of Revenue	1,395,665	1,360,558	1,343,737	1,216,563	1,151,550	1,065,870
Gross Profit	311,624	298,955	296,982	297,891	279,995	272,312
Selling, General & Admin	255,602	249,309	246,225	233,331	225,167	213,458
Research & Development	10,576	9,131	10,128	15,275	9,678	8,322
Amortization of Goodwill & Intangibles	1,586	1,187	1,024	473.49	1,233	1,185
Other Operating Expenses	1,771	1,522	2,059	1,989	1,391	1,589
Operating Expenses	278,084	267,909	266,885	255,821	241,751	227,376
Operating Income	33,540	31,046	30,097	42,070	38,244	44,936
Interest Expense	-11,389	-11,005	-10,274	-6,904	-3,735	-2,544
Interest & Investment Income	6,537	4,954	6,319	5,399	2,844	2,415
Earnings From Equity Investments	-6,211	-11,441	767.76	-429.82	-435.51	-112.22
Currency Exchange Gain (Loss)	3,925	-1,516	3,159	-384.81	6.49	693.27
Other Non Operating Income (Expenses)	-102.48	1,403	-1,169	-179.12	1,132	-865.71
EBT Excluding Unusual Items	26,300	13,441	28,900	39,571	38,056	44,522
Gain (Loss) on Sale of Investments	7,840	7,050	25,399	9,412	-1,932	-10,232
Gain (Loss) on Sale of Assets	886.54	7,677	3,026	-1,964	166.52	38.87
Asset Writedown	-2,590	-2,590	-	-	-	-
Pretax Income	32,909	30,985	57,325	49,019	36,291	34,329
Income Tax Expense	9,973	9,656	15,480	9,648	9,590	8,788
Earnings From Continuing Operations	22,936	21,329	41,845	39,372	26,701	25,541
Minority Interest in Earnings	-1,113	-360.35	-1,364	-2,406	-2,527	-1,522
Net Income	21,823	20,968	40,481	36,966	24,174	24,019
Net Income to Common	21,823	20,968	40,481	36,966	24,174	24,019
Net Income Growth	-19.80%	-48.20%	9.51%	52.91%	0.65%	-47.06%
Shares Outstanding (Basic)	45	40	40	40	41	41
Shares Outstanding (Diluted)	46	40	40	40	41	41
Shares Change	14.97%	0.50%	-1.06%	-1.48%	-0.11%	1.48%
EPS (Basic)	480.38	521.09	1011.00	913.39	588.45	584.68
EPS (Diluted)	478.54	521.09	1011.00	913.00	588.00	584.33
EPS Growth	-30.25%	-48.46%	10.73%	55.27%	0.63%	-47.78%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	1,022	52,479	-87,883	-46,515	37,439	31,145
Free Cash Flow Per Share	22.41	1304.16	-2194.85	-1149.35	911.36	757.27
Dividend Per Share	-	-	-	-	100.000	100.000
Dividend Growth	-	-	-	-	0%	0%
Gross Margin	18.25%	18.02%	18.10%	19.67%	19.56%	20.35%
Operating Margin	1.97%	1.87%	1.83%	2.78%	2.67%	3.36%
Profit Margin	1.28%	1.26%	2.47%	2.44%	1.69%	1.80%
Free Cash Flow Margin	0.06%	3.16%	-5.36%	-3.07%	2.61%	2.33%
EBITDA	54,071	49,101	44,629	54,974	52,262	59,045
EBITDA Margin	3.17%	2.96%	2.72%	3.63%	3.65%	4.41%
D&A For EBITDA	20,531	18,055	14,532	12,904	14,017	14,110
EBIT	33,540	31,046	30,097	42,070	38,244	44,936
EBIT Margin	1.97%	1.87%	1.83%	2.78%	2.67%	3.36%
Effective Tax Rate	30.30%	31.16%	27.00%	19.68%	26.43%	25.60%
Advertising Expenses	-	42,261	45,513	46,186	42,214	40,464